Group 1: Oscar Health Overview - Oscar Health is revolutionizing the health insurance industry by achieving high customer satisfaction, with a Net Promoter Score of 66, significantly higher than traditional insurers [3][4] - The company serves over 2 million members across 504 counties in 18 states, with a tech-first approach that lowers administrative costs and improves member engagement [5] - Oscar trades at a low valuation of 14.4 times projected 2027 earnings, indicating the market undervalues its growth potential and competitive advantages [6][14] Group 2: Market Context for Oscar Health - The Affordable Care Act marketplace has expanded to 24.3 million enrollees, more than double the 11.4 million in 2020, positioning Oscar to capture underserved markets [7] - Oscar's multilingual support and culturally tailored products enhance its ability to attract customers from diverse communities [7] Group 3: Advanced Micro Devices (AMD) Overview - AMD is gaining traction in the AI chip market, with its MI350 series GPU launch moved to mid-2025 due to strong demand [8][9] - The company reported data center revenue of $3.9 billion in Q4 2024, a 69% year-over-year increase, and over $5 billion in AMD Instinct accelerator revenue for the full year [10] Group 4: Market Positioning of AMD - AMD trades at 25.5 times projected 2027 earnings, which is a 13% discount compared to Nvidia's 29.2 times, presenting a compelling investment opportunity [11][14] - The company offers integrated CPU-GPU solutions, providing unique advantages in the evolving AI infrastructure market [12] Group 5: Comparative Analysis of Oscar Health and AMD - Both Oscar Health and AMD operate in large markets with innovative approaches that the market has not fully recognized [13] - They trade at significant discounts to their growth potential, making them attractive options for investors seeking value [14]

Core Insights - The article discusses the expertise of a DevOps Engineer specializing in AI tools and applications, highlighting their deep knowledge in generative AI systems and machine learning algorithms [1] - The engineer is pursuing advanced AWS machine learning certifications to enhance their expertise in AI and machine learning [1] - The engineer contributes insights on AI and machine learning through an investment-focused lens on Seeking Alpha [1] Group 1 - The engineer works for a major subsidiary of a large-cap Fortune 500 company, indicating a strong corporate backing and resources [1] - The engineer ranks highly among financial bloggers and experts, showcasing their credibility and influence in the investment community [1] - The article emphasizes that the engineer has no financial positions in the companies mentioned, ensuring an unbiased perspective [1] Group 2 - The engineer's focus on the buildout, deployment, and maintenance of AI tools suggests a practical approach to AI implementation in business [1] - The mention of machine learning algorithms and model training indicates a technical depth that could be valuable for companies looking to adopt AI solutions [1] - The article reflects a growing trend in the industry towards advanced certifications in machine learning, highlighting the importance of continuous education in the tech field [1]

Core Viewpoint - OSCR is identified as a company with significant potential, and despite a recent substantial stock rally, it is still considered undervalued [1]. Group 1 - The Pragmatic Investor focuses on global macro trends, international equities, commodities, technology, and cryptocurrencies, aiming to assist investors at all levels [1]. - The investment group emphasizes building robust and diversified portfolios to preserve and increase wealth over time [1]. Group 2 - The article is authored by an economist with a decade of experience analyzing global markets, leading to insights on investment opportunities [1].

Core Viewpoint - Oscar Health is positioned as a contrarian investment opportunity in the health insurance sector, demonstrating strong growth and profitability, particularly in light of potential regulatory changes that could expand its market significantly [1][15]. Company Overview and Q1 2025 Performance - Oscar Health is a tech-native health insurer focusing on individual and family plans through ACA exchanges, currently operating in 18 states and insuring approximately 2 million members, representing about 1 in every 13 ACA enrollees nationwide [4]. - In Q1 2025, Oscar reported $275.3 million in net income, a significant increase from $177.4 million a year prior, with total revenue reaching $3.05 billion, reflecting a robust 42% year-over-year growth [5]. - The company achieved a record-low SG&A ratio of 15.8%, down from 18.4%, indicating improved operational efficiency under new leadership [6]. Market Opportunity Analysis - The introduction of the Choose Medicare Act proposes a Medicare Part E public option, which could significantly increase Oscar's addressable market, potentially tripling it if the legislation passes [10]. - Oscar's digital infrastructure and technology position it well to capitalize on the expected influx of consumers seeking coverage through public marketplaces [10]. Valuation Discussion - Oscar trades at 14 times projected 2027 earnings, which is considered a bargain given its high double-digit revenue growth [11]. - The company's market cap of $4.8 billion is less than 50% of its current annual revenue, suggesting a valuation disconnect compared to traditional insurers [11]. Investment Considerations - The risk-reward profile favors buyers, with the potential for Oscar's valuation to increase significantly if the public option is realized, transforming it from a $5 billion to a $15 billion company within 18 months [13]. - Even without the Medicare Part E, Oscar's compelling growth metrics and operational improvements make it an attractive investment opportunity [13][15]. - The market currently undervalues Oscar as a traditional insurer, while it operates as a technology company in the insurance space, creating a unique investment opportunity [14].

In this video, I will cover Oscar Health (OSCR 16.70%) and why I find this a compelling investment opportunity. Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of June 17, 2025. The video was published on June 17, 2025. ...

Group 1 - Oscar Health (NYSE: OSCR) was initially rated as a "Buy" in March 2025, with the stock price falling to $12 before recovering to the $16 range [1] - MMMT Wealth, managed by Oliver, focuses on investment strategies and stock analysis, leveraging insights from investor calls, presentations, and financials [1] - Oliver has 5 years of investing experience and 4 years as a CPA, emphasizing the importance of thorough research in identifying high-potential businesses [1]

Company Overview - Oscar Health, Inc. (OSCR) shares increased by 7.8% to close at $16.11, following a significant volume of trading, contrasting with a 14.7% loss over the previous four weeks [1] - The company is positioned to capitalize on a substantial opportunity in the healthcare market, as approximately 12% of household income is spent on employer-sponsored health plans [2] Growth Strategy - Oscar's growth strategy focuses on building sustainable and scalable operations, enhancing member experience, advancing technology, and introducing innovative offerings to expand its market presence [3] Financial Performance Expectations - The upcoming quarterly earnings report is expected to show earnings of $0.34 per share, reflecting a year-over-year increase of 70%, with revenues projected at $2.86 billion, a 29% increase from the same quarter last year [4] - However, the consensus EPS estimate has been revised 0.7% lower in the last 30 days, indicating a potential negative trend in earnings estimate revisions [5] Industry Context - Oscar Health is part of the Zacks Insurance - Multi line industry, which includes other companies like MBIA (MBI), that has seen a decline of 6.7% over the past month [6] - MBIA's EPS estimate for the upcoming report remains unchanged at -$0.08, representing a 97.2% change from the previous year [7]

Core Insights - Hims & Hers Health has seen a significant increase in share price, up 138% in 2025, contrasting with other major healthcare stocks that have not performed as well [3][2] - Oscar Health is positioned as a potential multibagger in the healthcare sector, drawing comparisons to Hims & Hers due to its technology-first approach in transforming access to health insurance [4][9] Company Overview - Hims & Hers focuses on telemedicine services, appealing to younger demographics by providing convenient access to healthcare [6][7] - Oscar Health targets Affordable Care Act (ACA) members and small employers, aiming to leverage a tech-first digital platform to enhance customer acquisition [10][9] Financial Performance - Oscar Health has shown strong revenue growth over the past five years, with rising cash flow and liquidity, indicating a solid financial profile despite competition [12] - The total addressable market (TAM) for Oscar could expand from $160 billion to $720 billion by targeting individual coverage health reimbursement arrangements (ICHRAs) with small and medium-sized businesses [16] Market Position and Strategy - Oscar Health's market capitalization is approximately $4 billion, which is aligned with its cash balance, suggesting that the market may undervalue its insurance business [17] - The company is diversifying its revenue streams to mitigate risks associated with potential regulatory changes affecting the ACA [14][19] Investment Outlook - There are potential near-term challenges for Oscar Health, but the long-term vision is seen as compelling, with expectations for significant share price appreciation similar to Hims & Hers [19][18]

Group 1 - The focus is on growth and dividend income, with a strategy aimed at creating a portfolio that emphasizes compounding dividend income and growth [1] - The portfolio is structured to provide monthly dividend income that increases through dividend reinvestment and annual raises [1] Group 2 - There is an intention to potentially start a position in OSCR in the near future [2] - The article serves as personal opinion and is not intended as a recommendation for stock purchase or sale [2] Group 3 - Past performance is not indicative of future results, and no specific investment advice is provided [3] - The views expressed may not represent those of Seeking Alpha as a whole, and the analysts may not be licensed or certified [3]

Group 1 - Healthcare stocks in the U.S. are experiencing pressure due to increasing regulatory headwinds and rising costs [1]